Growth hormone may come from a gland roughly the size of a pea, but it has a surprisingly large job description. In children, it supports normal linear growth. In adults, it contributes to healthy body composition, bone strength, metabolism, and overall well-being. When the body does not produce enough of it, treatment may require replacing the missing hormone rather than simply waiting for the pituitary gland to reconsider its career choices.
Skytrofa, the brand name for lonapegsomatropin-tcgd, is a long-acting growth hormone therapy administered once a week. It is approved in the United States for certain children with growth failure caused by inadequate growth hormone secretion and for adults with confirmed growth hormone deficiency. Its weekly schedule distinguishes it from traditional somatropin products that are commonly injected every day.
That convenience does not turn growth hormone treatment into a casual do-it-yourself project. Diagnosis, dosing, laboratory monitoring, and follow-up should be managed by an endocrinology professional who understands growth hormone disorders and the other pituitary hormones that may be involved.
Understanding Growth Hormone Deficiency
What growth hormone does in children
Growth hormone is produced by the pituitary gland and released in pulses, particularly during sleep. It stimulates the liver and other tissues to produce insulin-like growth factor 1, commonly called IGF-1. Together, growth hormone and IGF-1 help the bones and other tissues grow.
A child with growth hormone deficiency may grow more slowly than expected, fall progressively lower on the growth chart, or remain much shorter than children of the same age. Unlike children whose poor growth is caused by inadequate nutrition, children with growth hormone deficiency may have a normal weight or carry additional weight around the abdomen.
Short stature alone does not prove that a child has growth hormone deficiency. Family height, constitutional growth delay, thyroid disease, celiac disease, chronic illness, genetic conditions, poor nutrition, and other factors can also affect growth. A careful evaluation matters because growth hormone is a prescription treatment, not a height-enhancing accessory.
How growth hormone deficiency affects adults
Adult growth hormone deficiency may continue from childhood or develop after a pituitary tumor, brain injury, surgery, radiation treatment, or another condition affecting the hypothalamus or pituitary gland. Adults do not become shorter from growth hormone deficiency, but they may experience unfavorable changes in body composition, reduced muscle mass, increased abdominal fat, lower bone density, reduced exercise capacity, fatigue, or impaired quality of life.
These symptoms overlap with many other medical conditions. Consequently, an adult who feels tired and dislikes stubborn belly fat should not assume the pituitary gland is responsible. Most adults require formal testing before growth hormone replacement is prescribed.
How Growth Hormone Deficiency Is Diagnosed
Diagnosis begins with the medical history, physical examination, previous growth records, current medications, and possible causes of pituitary dysfunction. In children, the evaluation may include accurate height measurements over time, calculation of growth velocity, parental heights, puberty assessment, laboratory tests, and a bone-age X-ray of the hand and wrist.
A random growth hormone blood level is usually not useful because the hormone is released in bursts. A perfectly healthy person can have a very low level between pulses. Doctors may instead measure IGF-1 and related markers, although these results must be interpreted in the context of age, nutrition, puberty, liver function, and other health factors.
Growth hormone stimulation testing may be performed when the diagnosis remains uncertain. During this test, medication is given to encourage the pituitary gland to release growth hormone, and several blood samples are collected over a period of time. Imaging of the pituitary region may also be recommended when a structural abnormality, tumor, or multiple pituitary hormone deficiencies are suspected.
Adults commonly need stimulation testing unless they have a clearly documented genetic or structural cause that makes the deficiency highly likely. Other pituitary hormones, including thyroid, adrenal, and reproductive hormones, should also be evaluated because the pituitary rarely respects departmental boundaries.
What Is Skytrofa?
Skytrofa contains lonapegsomatropin-tcgd, a long-acting prodrug of somatropin. A prodrug is designed to release its active medication after administration. In this case, the product gradually releases somatropin, which has the same amino-acid sequence as naturally occurring human growth hormone.
The extended-release design allows Skytrofa to be injected once weekly. It does not remain permanently attached to an inactive carrier while acting on growth hormone receptors. Instead, active somatropin is released over the course of the week and performs the familiar biological work associated with growth hormone.
In the United States, Skytrofa is indicated for:
- Children at least 1 year old who weigh at least 11.5 kilograms, or approximately 26 pounds, and have growth failure caused by inadequate secretion of their own growth hormone.
- Adults who require replacement of endogenous growth hormone because of confirmed growth hormone deficiency.
Skytrofa is not approved as an anti-aging treatment, bodybuilding aid, general weight-loss medication, or treatment for every cause of short stature. More hormone is not automatically more health. Sometimes it is simply more side effects wearing an expensive lab coat.
Skytrofa Dosing and Administration
Pediatric dosing
The FDA-recommended pediatric dose is 0.24 milligrams per kilogram of body weight once weekly for both treatment-naive children and those switching from another growth hormone product. The prescriber selects the appropriate cartridge strength based on the child’s weight, treatment response, growth goals, and clinical circumstances.
Because children gain weight and progress through puberty, their dose may need to change. Families should never move to a different cartridge strength simply because the child has grown or because the current box suddenly looks too familiar. Dose changes belong on the endocrinologist’s side of the clipboard.
Adult dosing
Adult starting doses are individualized according to age and whether the person takes oral estrogen. Younger adults and people using oral estrogen may require a different starting dose than older adults. The dose is generally adjusted monthly according to clinical response, side effects, and IGF-1 results. The FDA labeling recommends collecting the adult IGF-1 sample four to five days after the preceding dose so that the result better represents the weekly average.
Using the auto-injector
Skytrofa cartridges are used with the reusable Skytrofa Auto-Injector. The device assists with reconstitution, mixing, and delivery of the medication. Patients and caregivers should receive hands-on training and review the official instructions rather than relying on a video made by someone whose primary credential is owning a ring light.
If a cartridge has been refrigerated, it should remain at room temperature for about 15 minutes before use. After mixing, the solution should appear clear and colorless to slightly opalescent. It should not be injected if it is cloudy or contains particulate matter. A reconstituted cartridge should be used within four hours when kept at room temperature.
The injection is given under the skin of the abdomen, buttock, or thigh. Injection locations should be rotated between and within these areas to reduce the risk of localized fat-tissue changes. Needles and used cartridges should be placed in an appropriate sharps container and never reused.
What Happens When a Dose Is Missed?
The FDA instructions provide some scheduling flexibility. A missed dose may generally be administered as soon as possible when no more than two days have passed. A dose can also be taken up to two days before or two days after the usual scheduled day, followed by a return to the regular weekly schedule.
When more than two days have passed, the missed dose should be skipped and the next dose given on the regularly scheduled day. At least five days should separate two injections. Patients should not double the dose to make up for lost time. Growth hormone treatment is not a loyalty-points program; two injections do not earn bonus height.
Anyone uncertain about timing should contact the prescribing clinic or pharmacist, particularly when illness, travel, device problems, or a recent change from another growth hormone product complicates the schedule.
How Effective Is Skytrofa?
Evidence in children
In the pivotal 52-week pediatric trial, 161 previously untreated, prepubertal children with growth hormone deficiency received either weekly Skytrofa or daily somatropin. The weekly Skytrofa group achieved an estimated annualized height velocity of 11.2 centimeters per year, compared with 10.3 centimeters per year in the daily somatropin group.
Height standard-deviation scores also improved in both treatment groups. Longer-term extension research has reported sustained growth improvements for children continuing lonapegsomatropin, including participants who originally received daily somatropin and later switched to weekly treatment.
Clinical-trial averages are useful, but they are not crystal balls. An individual child’s response depends on age at treatment initiation, severity of deficiency, genetics, puberty timing, nutrition, adherence, bone age, other medical conditions, and how much growth potential remains before the growth plates close.
Evidence in adults
In an adult phase 3 study, 259 participants with growth hormone deficiency received weekly Skytrofa, placebo, or open-label daily somatropin. After 38 weeks, trunk fat percentage decreased in the Skytrofa group while it increased slightly in the placebo group. The trial also evaluated lean body mass, fat mass, IGF-1, and safety outcomes.
The adult study was not designed to establish that weekly Skytrofa was better than daily somatropin through a formal head-to-head statistical comparison. Adult treatment goals are also broader than changing a single body-composition measurement. The clinician considers symptoms, physical functioning, bone health, metabolic factors, IGF-1, treatment burden, and adverse effects.
Side Effects and Important Safety Concerns
Common reactions reported in the pediatric clinical trial included viral infection, fever, cough, nausea or vomiting, diarrhea, abdominal pain, and joint symptoms. In the adult study, peripheral swelling was among the more common reactions, and thyroid-function changes were also observed.
Growth hormone products can cause fluid retention, joint pain, muscle discomfort, tingling, or carpal-tunnel-type symptoms. These effects may be dose related and can be more noticeable in adults. The prescriber may reduce the dose rather than asking the patient to bravely negotiate with swollen fingers.
Additional risks and monitoring considerations include:
- Glucose changes: Growth hormone may reduce insulin sensitivity and reveal previously unrecognized impaired glucose tolerance or type 2 diabetes.
- Intracranial hypertension: Severe headache, vision changes, nausea, or vomiting require prompt medical evaluation.
- Thyroid and adrenal function: Treatment can uncover or worsen central hypothyroidism or reveal inadequate cortisol production in susceptible patients.
- Hip or knee symptoms in children: A new limp or persistent hip or knee pain may indicate slipped capital femoral epiphysis and should be assessed promptly.
- Scoliosis: Rapid growth can allow preexisting scoliosis to progress, although somatropin has not been shown to cause scoliosis itself.
- Pancreatitis: Persistent severe abdominal pain warrants medical attention.
- Allergic reactions: Facial swelling, breathing difficulty, widespread hives, or other signs of a serious reaction require emergency care.
- Tumor surveillance: People with a history of tumors, particularly childhood cancer survivors treated with cranial radiation, need individualized risk assessment and monitoring.
Skytrofa should not be used in several circumstances described in its prescribing information, including active malignancy, acute critical illness after certain major medical events, severe hypersensitivity to its ingredients, and active proliferative or severe nonproliferative diabetic retinopathy. It is also contraindicated for promoting growth in children whose growth plates have closed.
Monitoring Treatment Over Time
Successful growth hormone replacement involves more than remembering injection day. For children, follow-up commonly includes height, weight, growth velocity, puberty stage, IGF-1, thyroid testing, injection technique, adherence, and possible bone-age assessment. Doctors also look for other explanations when growth response is weaker than expected, including inadequate nutrition, hypothyroidism, advanced bone age, missed medication, or an incorrect diagnosis.
Adult monitoring may include IGF-1, symptoms, swelling, joint complaints, glucose levels, thyroid and adrenal function, body composition, bone health, and quality of life. The goal is to find the lowest appropriate dose that produces meaningful clinical benefit without pushing IGF-1 above the age- and sex-adjusted target range.
Children treated for growth hormone deficiency should be reevaluated when linear growth is complete. Some continue to have permanent deficiency and benefit from adult replacement, while others no longer meet adult diagnostic criteria.
Storage and Travel Considerations
Skytrofa cartridges should generally be stored in their outer carton in a refrigerator at 36°F to 46°F to protect them from light. They should not be frozen. The cartons may alternatively be kept at room temperature, up to 86°F, for as long as six months, provided the product is not used beyond its labeled expiration date or the six-month room-temperature limit.
The date the carton first leaves refrigeration should be written on the designated area. The product may be returned to refrigeration during that six-month period. Travelers should carry medication in hand luggage, protect it from extreme heat and freezing, bring enough needles and supplies, and keep prescription documentation available. Airline baggage compartments and parked cars are famous for treating temperature recommendations as creative suggestions.
Experiences With Treating Growth Hormone Deficiency With Skytrofa
The following examples are composite, educational scenarios based on common treatment issues. They are not quotations from specific patients and should not replace individualized medical advice.
A family beginning treatment for the first time
For a family whose child has just been diagnosed, the first few weeks may feel less like a medical routine and more like learning to operate a tiny spacecraft. There is a device to charge, a cartridge to prepare, an injection site to select, and a child who may suddenly remember several urgent reasons to leave the room.
The initial training session can make a large difference. A nurse may demonstrate the auto-injector, supervise the first preparation, explain how the device signals that the injection is complete, and review safe needle disposal. At home, the family may choose a predictable evening, place a repeating reminder on the calendar, and allow the child to select the injection site or press a button when age appropriate.
Visible height changes are not usually dramatic from one week to the next. Families often find it more useful to focus on measurements collected at clinic visits rather than conducting daily doorway inspections. During the first year, an improving growth velocity may be more meaningful than a single percentile or comparison with a taller classmate.
Switching from daily injections
A child switching from daily somatropin may appreciate reducing the number of injections from seven per week to one. Parents may also find that fewer injections mean fewer opportunities for forgotten doses during homework, sleepovers, sports, and the nightly debate over whether teeth truly require brushing.
However, weekly treatment creates a different kind of routine. Missing one weekly injection represents a larger portion of the month’s therapy than missing one daily dose. Families may need a prominent calendar reminder, a backup alarm, and a plan for vacations or shared-custody households. They also need clear instructions about the interval between the last daily dose and the first weekly dose.
Some children are relieved by the reduced injection frequency but remain nervous on injection day. Distraction, numbing strategies approved by the clinical team, allowing choices, and calm caregiver behavior may help. Pressure, threats, and surprise injections generally make the next week more difficult.
An adult starting weekly replacement
An adult with pituitary disease may begin Skytrofa hoping for better energy or body composition. Early treatment is usually a process of gradual dose adjustment rather than an overnight transformation. The person may return for laboratory testing, discuss swelling or joint stiffness, and have the dose modified according to IGF-1 and clinical response.
Some adults may notice subtle improvements in stamina, daily functioning, or well-being over time. Others may experience side effects before benefits become clear. Expectations matter: Skytrofa replaces deficient growth hormone, but it does not erase ordinary aging, substitute for sleep, or negotiate a truce with every stressful meeting on the calendar.
The most sustainable experience tends to involve shared decision-making. Patients who understand why they are being treated, how success will be measured, which symptoms require attention, and what to do after a missed dose are better equipped to participate in long-term care. Convenience is valuable, but confidence and communication are what turn a weekly injection into a workable treatment plan.
Conclusion
Skytrofa offers once-weekly growth hormone replacement for eligible children and adults with confirmed growth hormone deficiency. Pediatric research demonstrates substantial improvement in growth velocity, while adult research supports clinically meaningful effects on body composition compared with placebo. The weekly schedule may reduce injection burden, but treatment still requires accurate diagnosis, individualized dosing, proper device training, consistent follow-up, and careful safety monitoring.
Patients and caregivers should contact their endocrinology team when growth is not improving as expected, side effects develop, laboratory results are abnormal, or dosing instructions are unclear. Seek urgent medical attention for severe allergic symptoms, major vision changes, intense headache with vomiting, or other rapidly worsening symptoms.
